Levobunolol
- Level
- Commodity
- Parent
- 51263100
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51263125This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C17H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6317AOI7K, chemically known as 3,4-dihydro-5-(3-(tert-butylamino)-2-hydroxy)propoxy-1(2h)-naphthalenone but generally known as levobunolol, which bears US NIH Compound Identifier 3914. European Medicines Agency schedules Levobunolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08463MIG. The term LEVOBUNOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules levobunolol in its Anatomical Therapeutic Chemical (ATC) Classification. LEVOBUNOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levobunolol under HS 29221980 and SITC 51461. As of Q4 2014, LEVOBUNOLOL remains the US FDA Preferred Term for this commodity. Levobunolol bears US NLM identifiers UMLS ID C0006388 and NCI Concept Code C62043. SMILES: O(C1C2CCCC(=O)C2CCC1)CC(O)CNC(C)(C)C.
Same parent
Under 51263100 · 75Activities that produce or sell this
KBLI · 8Inherited from family 51260000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.